Jensen, Pernille Tine by unknown
Syddansk Universitet
Danish Gynecological Cancer Database
Sørensen, Sara Mejer ; Frahm Bjørn, Signe; Jochumsen, Kirsten; Jensen, Pernille Tine;
Thranov, Ingrid; Hare-Bruun, Helle; Seibæk, Lene; Høgdall, Claus
Published in:
Clinical Epidemiology
DOI:
10.2147/CLEP.S99479
Publication date:
2016
Document version
Final published version
Document license
CC BY-NC
Citation for pulished version (APA):
Sørensen, S. M., Frahm Bjørn, S., Jochumsen, K., Jensen, P. T., Thranov, I., Hare-Bruun, H., ... Høgdall, C.
(2016). Danish Gynecological Cancer Database. Clinical Epidemiology, 8, 485-490. DOI: 10.2147/CLEP.S99479
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 06. Feb. 2017
© 2016 Sørensen et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Clinical Epidemiology 2016:8 485–490 (Thematic series on clinical quality databases in Denmark)
Clinical Epidemiology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
485
R E v i E w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CLEP.S99479
Danish Gynecological Cancer Database
Sarah Mejer Sørensen1
Signe Frahm Bjørn1
Kirsten Marie Jochumsen2
Pernille Tine Jensen2
ingrid Regitze Thranov1
Helle Hare-Bruun3
Lene Seibæk4
Claus Høgdall1
1Department of Gynecology, 
Rigshospitalet, University of 
Copenhagen, Copenhagen, Denmark; 
2Department of Obstetrics and 
Gynecology, Odense University 
Hospital, Odense, Denmark; 3Research 
Centre for Prevention and Health, The 
Capital Region of Denmark, Glostrup, 
Denmark; 4Department of Gynecology 
and Obstetrics, Aarhus University 
Hospital, Aarhus, Denmark
Correspondence: Sarah Mejer Sørensen 
Department of Gynecology, 
Rigshospitalet, University of Copenhagen, 
Blegdamsvej 9, 2100 Copenhagen, 
Denmark 
Tel +45 2297 9956 
Fax +45 3545 4285 
Email sarah.mejer.soerensen@regionh.dk
Aim of database: The Danish Gynecological Cancer Database (DGCD) is a nationwide clinical 
cancer database and its aim is to monitor the treatment quality of Danish gynecological cancer 
patients, and to generate data for scientific purposes. DGCD also records detailed data on the 
diagnostic measures for gynecological cancer.
Study population: DGCD was initiated January 1, 2005, and includes all patients treated at 
Danish hospitals for cancer of the ovaries, peritoneum, fallopian tubes, cervix, vulva, vagina, 
and uterus, including rare histological types.
Main variables: DGCD data are organized within separate data forms as follows: clinical 
data, surgery, pathology, pre- and postoperative care, complications, follow-up visits, and final 
quality check. DGCD is linked with additional data from the Danish “Pathology Registry”, 
the “National Patient Registry”, and the “Cause of Death Registry” using the unique Danish 
personal identification number (CPR number).
Descriptive data: Data from DGCD and registers are available online in the Statistical Analysis 
Software portal. The DGCD forms cover almost all possible clinical variables used to describe 
gynecological cancer courses. The only limitation is the registration of oncological treatment 
data, which is incomplete for a large number of patients.
Conclusion: The very complete collection of available data from more registries form one of 
the unique strengths of DGCD compared to many other clinical databases, and provides unique 
possibilities for validation and completeness of data. The success of the DGCD is illustrated 
through annual reports, high coverage, and several peer-reviewed DGCD-based publications.
Keywords: quality, research, gynecological cancer, operation, pathology, follow-up
Aim of database
The aim of the Danish Gynecological Cancer Database (DGCD) is to achieve the 
greatest possible knowledge regarding examination, treatment methods, and results 
within the field of gynecological cancer in Denmark. The purpose is treatment quality 
assurance and improvement, and generation of scientific data.1
Study population
DGCD is by definition nationwide: “a clinical quality registry where a minimum of 90% 
of the relevant patient population in Denmark is registered”.2 The database was initiated 
on January 1, 2005. The database before June 1, 2013, is referred to as the old DGCD 
and the database after this date as the new DGCD. Data from the old DGCD are mapped 
into the new DGCD in order to assure continuity. Since July 2015, 19,729 patients had 
been registered in DGCD, on average 1,879 patients per year since January 1, 2005. 
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Table 1 shows an overview of the patients currently enrolled 
in DGCD and the diagnoses that DGCD covers.3,4 As seen in 
Table 2, DGCD has had a high coverage rate throughout the 
years. The coverage estimates are based on the registrations 
in the Danish National Patient Registry (NPR).
Main variables
Data are registered online in special data forms programmed 
in the TietoEnator’s quality measurement system.5 Data are 
placed on a central server hosted by the Registry Support 
Center (East) – Center for Clinical Quality Improvement 
and Health Informatics.
The data of DGCD are primarily recorded in four main 
online forms: clinical data, surgery, pathology, and final quality 
check. In the old DGCD, some of the variables were optional, 
thus resulting in varying registration of the optional variables. 
In the new DGCD, optional data requirements have been 
eliminated. Due to the setup of the old DGCD, it was possible 
to add and fill in data forms in a way in which the sequence of 
patient events were incorrectly registered. In order to get valid 
data, constant data review and time consuming correction by 
doctors and secretaries was needed. The structure of the data 
forms in the new DGCD ensures correct registration.
The first data form covers clinical data. The data are 
registered by gynecologists specializing in gynecological 
oncology. The second data form covers surgical data recorded 
by surgeons specializing in gynecological oncology. The 
third data form covers pathology data that are registered by 
a pathologist. All data forms are designed to logically and 
consecutively provide variables specific for each type of 
gynecological cancer and surgery.
Staging follows the “International Federation of 
 Gynecology and Obstetrics” (FIGO) system. Staging reports 
are available both in the FIGO and Tumor Nodes Metastasis 
system. In case of ovarian cancer, the final staging is based 
on both surgical and pathological staging. In uterine cancers, 
the pathological staging is determinative. When the diagnosis 
is based only on a biopsy, the gynecological clinician can 
choose to stage the disease based on imaging and clinical 
findings. The staging follows the FIGO guidelines. Staging 
and treatment of cervical, vulva, and ovarian cancer is central-
ized in Denmark and only allowed in centers with specialized 
gynecological oncologists.
The fourth data form is the final quality check, which 
is recorded by the gynecologists. Data from all data forms 
described earlier are consolidated and from this the final 
staging and diagnosis is performed.
In the new DGCD, data forms for registering pre- and 
postoperative nurses’ care and data forms for vulva/vagi-
nal cancer and trophoblastic disease were added in 2013. 
Table 1 The DGCD’s present patient population according to diagnosis
2014/2015 2013/2014 2012/2013 2011/2012a 2005–2011a Total
n % n % n % n % n % N %
Ovarian cancer 324 16.6 346 16.3 420 28.6 495 27.2 3,067 24.9 4,652 23.6
Tubal cancer 27 1.4 40 1.9 28 1.9 23 1.3 197 1.6 315 1.6
Peritoneal cancer 45 2.3 40 1.9 6 0.4 1 0.1 313 2.5 405 2.1
Borderline tumors 124 6.3 159 7.5 119 8.1 133 7.3 1,114 9 1,649 8.4
Cancer of the cervix 337 17.3 367 17.3 246 16.8 347 19.0 2,467 20 3,764 19.1
vulvar cancer 128 6.6 114 5.4 56 3.8 46 2.5 – – 344 1.7
vaginal cancer 21 1.1 14 0.7 – – 1 0.1 – – 36 0.2
Trophoblast disease 28 1.4 48 2. 5 0.3 1 0.1 – – 82 0.4
Unknown ovarian or  
peritoneal cancer
94 4.8 99 4.7 7 0.5 – – – – 200 1.0
Endometrial cancer 718 36.8 788 37.1 566 38.6 775 42.5 4,718 38.2 7,565 38.4
Uterine hyperplasia  
with atypia
107 5.5 109 5.1 13 0.9 1 0.1 463 3.8 693 3.5
Total 1,953 100 2,124 100 1,466 100 1,823 100 12,339 100 19,705 100
Note: aDue to the mapping of data from the old DGCD to the new DGCD, the number of patients enrolled in 2005–2011 and the number of patients enrolled in 
2011/2012 will have a small overlap.
Abbreviation: DGCD, Danish Gynecological Cancer Database.
Table 2 Data coverage during the life span of the database based 
on data from the database Quality Management System (QMS) 
and the Danish National Patient Registry (NPR)
DGCD national 
report period
Registered 
in both QMS 
and NPR, n
Only in  
QMS
Only in  
NPR
Coverage 
rate (%)
2014/2015 2,029 132 72 97
2013/2014 2,239 85 43 98
2012/2013a 1,715 113 231 89
2005–2012 14,869 N/A 480 97
Notes: aDue to increased scrutiny of the new database, there are fewer patients in 
the database from this period than previously reported. N/A: Data not available.
Abbreviation: DGCD, Danish Gynecological Cancer Database.
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An overview of the main variables in DGCD is presented 
in Table 3. The old DGCD also included a data form for 
 registration of data regarding the oncological treatment. 
Due to poor cover rate, this data form was omitted in the 
new DGCD. Oncologic data in the new DGCD are imported 
from the NPR which only includes date and type of onco-
logic treatment.
In addition, data such as diagnosis, duration of hos-
pitalization, and perioperative complications are drawn 
from the NPR. In this way, DGCD data are both validated 
and  supplemented. Pathological data regarding histology 
and relapse biopsies are drawn from the Danish Pathology 
 Register, data regarding cause of death from the Cause of 
Death Register, and overall survival from the Civil Registra-
tion System, which is updated day-to-day.
Follow-up
Data regarding follow-up are registered in DGCD with a 
form describing each follow-up visit, including registration 
of relapse and residual disease. The unique nationwide Civil 
Registration System and Cause of Death Register ensure 
virtually complete follow-up of all patients recorded in the 
DGCD. Until recently, Danish gynecologic cancer patients 
had follow-up visits at the hospital for 5 years or to recurrence 
and/or death. According to new guidelines from the National 
Institute of Health, follow-up visits after the first year will now 
be based on need.
Examples of research
DGCD has formed the basis of several scientific studies 
and publications. This spans from scholarship fellows and 
bachelor theses to PhD theses, doctoral theses, and post-doc 
publications. In 2014 alone, DGCD data were used in nine 
ongoing PhD projects and three ongoing post-docs.6
Several DGCD studies have been published for assur-
ance of quality. Fagö-Olsen et al demonstrated in 2011 that 
 centralization of treatment for ovarian cancer improves 
 survival. It was shown that patients with stage IIIC and IV ovar-
ian cancer benefit from treatment in a tertiary referral center.7
Another quality study based solely on DGCD data by 
Håkansson et al in 2012 validated the use of the risk of 
malignancy index (RMI) as a tool for ovarian cancer risk 
assessment and referral to a tertiary center. They found that 
RMI $200 was a reliable tool for identifying patients with 
ovarian cancer.8
In 2014, Svolgaard et al published an article for assurance 
of quality based on DGCD data. The aim was to evaluate the 
Danish nationwide progress in implementing lymphadenec-
tomy for women presenting with tumor(s) macroscopically 
confined to the ovary, and the effect of lymphadenectomy on 
the overall survival. The study concluded that the national 
number of lymphadenectomies was too low, although increas-
ing, and that the effect of lymphadenectomies on overall 
survival was not significant.9 The results of the study formed 
the basis for a very intense debate about systematic lymph-
Table 3 Main variables in DGCD – an overview
Clinical data Surgical data Pathology Pre- and  
postoperative  
care
Gynecological history Description of
Cancer spread, tumor size
Macro- and microscopically  
verified spread of the cancer
Psychosocial status
Predispositions Peritoneal carcinomatosis Cytology of peritoneal and  
pleural fluids
Nutritional status
Comorbidity Metastases Histology Mobilization
Smoking and alcohol Ascites Histological type vital functions
BMi Performed surgery wHO grade Pain score
Risk of malignancy  
index (RMi)
Extent of surgery FiGO stage
Data on preoperative  
physical findings
Resection of other organs
Choice of treatment Operative time
Surgical outcome
Residual tumor size
Residual carcinomatosis
incidental lesions to other organs
Operative surgical stage
Blood loss
Surgical complications (within  
30 days postoperative)
Abbreviations: DGCD, Danish Gynecological Cancer Database; BMi, body mass index; wHO, world Health Organization; FiGO, international Federation of Gynecology 
and Obstetrics.
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adenectomy and revision of guidelines. DGCD publishes 
annual reports, which are widely used as a source of quality 
results of Danish gynecologic cancer treatment.3
A DGCD validation study from 2014 concluded: the data 
on endometrial cancer registered in the DGCD  regarding 
surgery and pathology is valid and complete, and they 
provide a solid base for research.10 The completeness of 
data on pathology and surgery reported to the DGCD was 
97.3% and the agreement for the reported data in the DGCD 
was 88.3%.10
A DGCD validation study on postoperative complications 
in ovarian cancer, tubal cancer, and ovarian borderline tumor 
patients showed that the completeness of reporting to the 
DGCD was 94.2% and the strength of agreement between 
the variables in the DGCD and the medical file varied from 
moderate to very good.11 A new large validation study on 
ovarian cancer based on a combination of NPR and DGCD 
variables is currently under progress (personal communication 
by Sørensen et al, March 6, 2016). DGCD has also been used 
in studies  showing how comorbidity independently affects 
overall survival in women with uterine or ovarian cancer.12
DGCD is furthermore extensively used in translational 
and clinical national and international studies as data 
are  easily combined with data from the Danish Cancer 
Biobank.13–16 In one of the first DGCD-based translational 
studies from 2010 performed by Petri et al, data from DGCD 
combined with material from the Danish Cancer Biobank 
were used in comparison of proteomic biomarker panels in 
urine and serum for ovarian cancer diagnosis. The authors 
concluded that urine and serum proteomic panels can 
be used individually or in combination in ovarian cancer 
diagnostics.17
The Danish Multidisciplinary Cancer Group (DMCG) 
produced a report on cancer survival in Denmark in the 
period 1995–2012.18 This report included calculations of 
ovarian cancer survival based on DGCD data. The report 
showed that the 5-year survival for ovarian cancer was 37% 
in the period 2005–2009, that the mortality rates of ovarian 
cancer patients in Denmark have been decreasing since 1995, 
and the survival trends have been gradually increasing since 
2000. This report provided important information on trends 
in the management and prognosis of ovarian cancer. Edwards 
et al have continued working on the report.19 
Administrative issues and funding
The DGCD is funded by the Danish regions. The monitoring 
and improvement of the treatment quality of gynecological 
cancer is the key objective that ensures the funding of DGCD, 
Table 4 Clinical quality indicators used
Indicator  
area
Indicator name Standard
Cervical  
cancer
Cervical cancer, percentage of patients  
with removal of $18 lymph nodes during  
radical hysterectomy
$80%
Cervical cancer, 5-year survival FiGO  
stage i
$90%
Cervical cancer, 5-year survival FiGO  
stage ii–iii
$45%
Ovarian  
cancer
Ovarian cancer, primary radical surgery,  
FiGO stage iiiC–iv, surgery
$60%
Ovarian cancer, radical surgery after  
neoadjuvant chemotherapy, FiGO  
stage iiiC–iv
$60%
Ovarian cancer, performed radical  
lymphadenectomy, FiGO stage i–iiiA
$80%
Ovarian cancer, performed radical  
lymphadenectomy, FiGO stage iiiB–iv
$80%
Ovarian cancer, postoperative hospitalization  
#8 days after primary surgery
$80%
Ovarian cancer, postoperative hospitalization  
#8 days after surgery performed after  
neoadjuvant chemotherapy
$80%
Endometrial  
cancer
Endometrial cancer, no lymphadenectomy,  
for low risk patients FiGO stage i
$85%
Endometrial cancer, removal of pelvic  
lymph nodes for mid-high risk patients  
FiGO stage i or ii–iii
$80%
Nurses’  
treatment
Nurses, ovarian cancer – mobilization  
of non-extensively operated patients  
$3 hours on postoperative day 1
$60%
Nurses, ovarian cancer – number of  
patients with defecation #3 days  
postoperative
$80%
Suggestions of new indicators
vulvar cancer vulvar cancer, sentinel node biopsy 
performed on patients with FiGO  
stage iB, tumor size #4 cm and no palpable 
inguinal nodes
$70%
Trophoblastic  
disease
Trophoblastic disease (only molar);  
genetic analysis performed
$75%
Abbreviation: FiGO, international Federation of Gynecology and Obstetrics.
which is anchored to the national expert group, the Danish 
Gynecological Cancer Group, consisting of clinicians and 
researchers responsible for developing and maintaining 
national clinical guidelines for the treatment of  gynecological 
cancer. DGCD is under the auspices of the DMCG; an 
umbrella organization comprised of 24 national, disease-
specific cancer groups and clinical databases. The running 
and maintenance of DGCD is managed by the DGCD steering 
committee, which consists of a chairperson and 14 members 
appointed by the Danish Gynecological Cancer Group board 
and the Registry Support Centre (East) – Centre for Clinical 
Quality Improvement and Health Informatics.
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To ensure maximal coverage rate, shortage lists are 
created specifically for each hospital and continually updated. 
The steering committee develops the annual DGCD report 
and clinical quality indicators in cooperation with Registry 
Support Centre (East) – Epidemiology and Biostatistics. The 
present 13 quality indicators, which are used to monitor the 
quality of the management of gynecological cancer between 
different regions of Denmark and across hospitals, are pre-
sented in Table 4. The quality indicators are under constant 
validation and development.3
Conclusion
The DGCD is a large compulsory nationwide clinical data-
base with a high coverage of all gynecological cancers. The 
large number of variables provides a basis for several quality 
and research publications. The selected data from all the reg-
isters are, together with DGCD data, available in a structured 
form in the Statistical Analysis Software portal and as raw 
data. This very complete collection of available data from 
several registers forms one of the unique strengths of DGCD, 
compared to many other clinical databases. It provides unique 
possibilities for validation and completeness of data. Other 
unique strengths of the DGCD are the high coverage, almost 
100% follow-up, and that DGCD represents data from all 
Danish patients with a gynecologic malignancy with minimal 
risk of selection bias in research and presentations. One of the 
major problems in DGCD registration is the lack of specific 
oncology data such as more detailed oncologic treatment, 
oncologic complications, and response and relapse data
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